A phase II study of docetaxel plus lycopene in metastatic castrate resistant prostate cancer

We carried out a phase II study to investigate the activity of docetaxel plus lycopene in advanced castrate resistant adenocarcinoma of the prostate. Patients were chemotherapy and biological therapy naive. Docetaxel 75 mg/m(2) was given every 21 days with daily oral lycopene 30 mg. The primary endp...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhuang, Eric, Uchio, Edward, Lilly, Michael, Zi, Xiaolin, Fruehauf, John P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886492/
https://www.ncbi.nlm.nih.gov/pubmed/34649352
http://dx.doi.org/10.1016/j.biopha.2021.112226

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886492/
https://www.ncbi.nlm.nih.gov/pubmed/34649352
http://dx.doi.org/10.1016/j.biopha.2021.112226

Ejemplares similares